We were so happy to be the successful recipients of two grants recently, $70,000 to support the provision of our Nurse support service
and $200,000 to an application to support the CONTROL NETs study.
Here is an update from Principal Investigator, A/Prof Nick Pavlakis:
Great news was received with the award of a $200,000 grant from Tour de Cure to an application by the Unicorn Foundation to support the CONTROL NET study, a study conducted by the Australasian Gastrointestinal Trials Group (AGITG) through the NHMRC Clinical Trials Centre.
CONTROL
NETS:
Capecitabine ON
Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
(Clinical Trials.gov
identifier: NCT02358356) is a randomized, controlled, multi-centre parallel group
(in midgutNETs and pancreasNETs) phase II open label trial of 72 patients which
aims to improve outcomes for patients with advanced midgut or pancreatic NETs
by providing high quality evidence, currently lacking, on the relative overall
benefits and costs of LuTate (177Lu-Octreotate), the predictive role
of PET scans, tissue biomarkers, and patient quality of life.
66 of 72 patients have been enrolled in the study
so far, which has completed its accrual of midgut NET patients but requires 6
more patients with Pancreas NETs to complete the study accrual. The Tour De Cure Grant provides funding to enable
completion of the main study objectives.
The Unicorn Foundation has been crucial in
providing grant funding (close to $600,000) that has enabled this important study to proceed and
near its completion, where Grant applications to NHMRC, Cancer Australia and
NETRF have been unsuccessful.
